Medical News

Real-world Comparative Effectiveness of ARNI vs. ACEi/ARB in...
Clin Res Cardiol.

In this nationwide real-world study including a population of patients with HF with reduced or mildly reduced EF,...

01 Dec 2022

Impact of Diabetes on 10‐Year Outcomes Following STEMI
J Am Heart Assoc.

Patients with ST‐segment–elevation myocardial infarction who had diabetes had worse clinical outcome at 10 years...

30 Nov 2022

Effects of LA Function on PAP in AMI, Hypertrophic and Dilat...
BMC Cardiovasc Disord.

The left atrial (LA) function in HCM and DCM and LV fibrosis in DCM correlated with PASP independent of E/e′ and LA...

29 Nov 2022

Risk of Mortality and Other Adverse Outcomes from MI in Canc...
Int. J. Clin. Oncol

This meta-analysis shows that cancer increases the risk of all-cause mortality, recurrent MI, and major bleeding in...

29 Nov 2022

Key Trials

Efficacy of Triple vs Double Oral Therapy in Newly Diagnosed PAH Patients

Although both the treatment regimens - initial triple and double therapy significantly reduced the pulmonary vascular resistance (PVR) in newly...

Treatment with Sacubitril/valsartan Associated with Improved Hemodynamic Status in Patients with HFrEF

According to the study, HFrEF patients treated with sacubitril/valsartan had improved hemodynamic status, as assessed by the changes in the...

Global Longitudinal Strain: A Robust and Independent Prognostic Indicator in Patients with HFimpEF

Global longitudinal strain is a strong and independent predictor for future HF events and deteriorating cardiac function in patients with HFimpEF....

ARNI Superior to ACEI/ARB in reducing CV Outcomes in Patients with Acute Myocardial Infarction

The study demonstrated ARNI to be superior to ACE inhibitor or ARB for reducing long-term adverse cardiovascular outcomes in patients with acute MI...

Slide Library

Medical Management Strategy of CTEPH: Role of Riociguat

Riociguat, a stimulator of soluble guanylate cyclase, has been globally approved for the treatment of PAH and inoperable CTEPH and persistent/...

 
Email this page
Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH

Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the...

 
Email this page
Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of...

 
Email this page
Diabetic Dyslipidemia

Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...

 
Email this page

Our Publications

CARLOC-I (Carvedilol +Ivabradine) Monograph

Carvedilol/ivabradine have a proven chemical-pharmaceutical quality and are considered an approvable fixed-dose combination. Both carvedilol and...

Rivazest (Rivaroxaban) Monograph

Rivaroxaban is a potent, selective, orally active direct inhibitor of the activated serine protease Factor X (FXa), which plays a central role in...

Telyse (Tenecteplase) Monograph

In the management of STEMI in India, pharmacoinvasive strategy involving thrombolytics is the preferred therapy in cases of delays in primary PCI....

Mexiletine FAQ Booklet

Mexiletine is a class 1B antiarrhythmic agent, which blocks the sodium channels and is indicated in suppression of ventricular arrhythmias. The...

Patient Education

Understanding Angioplasty

Angioplasty is a life-saving procedure to open up blocked or narrowed blood vessels. This document gives a brief idea about the procedure.

Understanding Obesity

This document explains what is obesity, what is the impact of obesity on overall health and what are the benefits of weight loss. 

Hypertension

Know more about the risk factors, associated ill-effects and tips for management of hypertension or high blood pressure. 

Poll

What percent of your patients who need oral anticoagulation, receive warfarin?

<20%
21% (6 votes)
20-40%
25% (7 votes)
40-50%
14% (4 votes)
50-70%
11% (3 votes)
70-80%
21% (6 votes)
Almost all
7% (2 votes)
Total votes: 28